Cerenis Therapeutics: Half-Year Report on Liquidity Agreement with Gilbert Dupont

Regulatory News:

Under the liquidity contract signed between Cerenis Therapeutics (Paris:CEREN) and Gilbert Dupont, the following assets were booked to the liquidity account at 31^st December 2018:

• Number of shares: 85,203
• Cash balance in the liquidity account: 99,463.14 €

As a reminder, in the last half-year report, at 29^th June 2018, the liquidity account stood as follows:

• Number of shares: 85,656
• Cash balance in the liquidity account: 90,256.69 €

About Cerenis Therapeutics
Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. CERENIS’ expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy. CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development and several products in clinical phases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190111005383/en/